Abstract
Objectives Durable immune responses against SARS-CoV-2 are generally observed in previously infected individuals. Immunocompromised individuals may show less durable responses. Investigation of immune responses is needed to inform individuals on whether measures such as boosters may be advisable.
Methods Three SARS-CoV-2 ELISA tests were utilized to monitor responses in 82 individuals in the United States [nucleocapsid protein (N)-specific antibody and spike RBD (receptor binding domain)-specific neutralizing antibody (nAb), and spike-specific interferon-γ (IFN-γ) release by T cells]. De-identified case reports highlight results for this cohort; 21 previously infected and vaccinated, 57 never infected and vaccinated, 2 breakthrough infections post-vaccination and 2 neither infected nor vaccinated.
Results The vaccines generated nAb responses in naïve donors, and in previously infected individuals with waning responses, immunosuppression, or weak infection responses. The cutoff for the nAb potency was established at 41.1 IU/mL when calibrated to the WHO International Standard (IU) using the NCI SARS-CoV-2 Standard. This relationship has the critical potential to allow comparisons of nAb measures to be utilized in studies of correlates of protection. Further, previously infected donors demonstrated robust T cell activity, while vaccinated and infection-naïve individuals had lower responses.
Conclusions Calibrated ELISA tests may aid broad vaccination strategies given their low cost and wide accessibility. Additional studies that relate measures of the adaptive responses to immunity from serious disease and infection are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Biodesix Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The observational study (DROPLET, BDSX-CD-004) was approved by the Advarra Institutional Review Board (IRB) and all donors provided written informed consent. A statistical analysis plan (SAP) was not required for an observational study of all comers regardless of pre-existing immune conditions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
